Gevers, T. J., Chrispijn, M., Wetzels, J. F., & Drenth, J. P. (2012). Rationale and design of the RESOLVE trial: Lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease. BioMed Central.
Citação norma ChicagoGevers, Tom JG, Melissa Chrispijn, Jack FM Wetzels, and Joost PH Drenth. Rationale and Design of the RESOLVE Trial: Lanreotide As a Volume Reducing Treatment for Polycystic Livers in Patients With Autosomal Dominant Polycystic Kidney Disease. BioMed Central, 2012.
Citação norma MLAGevers, Tom JG, Melissa Chrispijn, Jack FM Wetzels, and Joost PH Drenth. Rationale and Design of the RESOLVE Trial: Lanreotide As a Volume Reducing Treatment for Polycystic Livers in Patients With Autosomal Dominant Polycystic Kidney Disease. BioMed Central, 2012.